December 17, 2021
1 minute watch
Source / Disclosures
Published by:
Advani A, et al. Abstract 3397. Presented at: ASH Annual Meeting and Exposition; December 11-14, 2021; Atlanta.
Disclosures: Advani reports research funding from AbbVie, Amgen, Glycomimetics, Immunogen, Kite Pharmaceuticals, Macrogenics, OBI, Pfizer and Seattle Genetics; Pfizer’s fees; and board member / advisory committees for Amgen, Glycomimetics, Kite and Seattle Genetics.
The researchers reported that the combination of the tyrosine kinase inhibitor dasatinib with prednisone and blinatumomab appeared safe in older patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
Based on the results of the Phase 2 study presented at the ASH Annual Meeting and Exhibition, Anjali Advani, MD, director of the inpatient leukemia program at the Taussig Cancer Institute at the Cleveland Clinic, told Healio in a video interview that there did not appear to be any increased toxicity and that the initial results “looked encouraging.”
“Right now we have about 1.7 years of median follow-up, so more follow-up is definitely needed,†Advani said. “But from the trial, at least the projected 3-year disease-free survival is excellent – around 85% – which, if this holds up with longer follow-up, would be very encouraging. So, we’re pretty excited about it.
